Alzheimer's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Alzheimer's Disease, including details on diagnosis, memory loss, heredity, treatment, medication.

Volume 2 (2005), Issue 1 (January)

1. Pick bodies in a family with presenilin-1 Alzheimer's disease.
   Ann Neurol, 57(1): 139-43. [Abstract] [Full-text]
2. AD lesions and infarcts in demented and non-demented Japanese-American men.
   Ann Neurol, 57(1): 98-103. [Abstract] [Full-text]
3. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing.
   Exp Neurol, 191: S95-S103. [Abstract] [Full-text]
4. Standardization and norms for a Hebrew naming test.
   Brain Lang, 92(2): 204-11. [Abstract] [Full-text]
5. Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains.
   Cereb Cortex, 15(2): 211-20. [Abstract] [Full-text]
6. The allele interaction between apolipoprotein epsilon2 and epsilon4 in Taiwanese Alzheimer's disease patients.
   Acta Psychiatr Scand, 111(1): 38-43. [Abstract] [Full-text]
7. Mechanism of disorientation in Alzheimer's disease.
   Eur Neurol, 52(4): 193-7. [Abstract] [Full-text]
8. Indicators of neuroprotection with galantamine.
   Brain Res Bull, 64(6): 519-24. [Abstract] [Full-text]
9. Alzheimer disease and Down syndrome: factors in pathogenesis.
   Neurobiol Aging, 26(3): 383-9. [Abstract] [Full-text]
10. Endosome function and dysfunction in Alzheimer's disease and other neurodegenerative diseases.
    Neurobiol Aging, 26(3): 373-82. [Abstract] [Full-text]
11. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease.
    Neurobiol Aging, 26(3): 355-61. [Abstract] [Full-text]
12. Glia and their cytokines in progression of neurodegeneration.
    Neurobiol Aging, 26(3): 349-54. [Abstract] [Full-text]
13. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study.
    Neurobiol Aging, 26(3): 341-7. [Abstract] [Full-text]
14. Developmental and vascular risk factors for Alzheimer's disease.
    Neurobiol Aging, 26(3): 325-34. [Abstract] [Full-text]
15. Developmental origins of aging in brain and blood vessels: an overview.
    Neurobiol Aging, 26(3): 281-91. [Abstract] [Full-text]
16. Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.
    Neurology, 64(1): 129-31. [Abstract] [Full-text]
17. Cerebral glucose metabolism in patients with AD and different APOE genotypes.
    Neurology, 64(1): 102-7. [Abstract] [Full-text]
18. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD.
    Neurology, 64(1): 94-101. [Abstract] [Full-text]
19. Bone mineral density and the risk of Alzheimer disease.
    Arch Neurol, 62(1): 107-11. [Abstract] [Full-text]
20. Characterization of the Alzheimer's disease-associated CLAC protein and identification of an amyloid beta-peptide-binding site.
    J Biol Chem, 280(2): 1007-15. [Abstract] [Full-text]
21. Increased cerebrospinal fluid levels of 3,3',5'-triiodothyronine in patients with Alzheimer's disease.
    J Clin Endocrinol Metab, 90(1): 198-202. [Abstract] [Full-text]
22. Candidate gene association study of solute carrier family 11a members 1 (SLC11A1) and 2 (SLC11A2) genes in Alzheimer's disease.
    Neurosci Lett, 374(2): 124-8. [Abstract] [Full-text]
23. Changes in extracellular space size and geometry in APP23 transgenic mice: a model of Alzheimer's disease.
    Proc Natl Acad Sci U S A, 102(2): 479-84. [Abstract] [Full-text]
24. F2-isoprostanes in Alzheimer and other neurodegenerative diseases.
    Antioxid Redox Signal, 7(1): 269-75. [Abstract] [Full-text]
25. The anti-inflammatory and cholinesterase inhibitor bifunctional compound IBU-PO protects from beta-amyloid neurotoxicity by acting on Wnt signaling components.
    Neurobiol Dis, 18(1): 176-83. [Abstract] [Full-text]
26. Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice.
    Neurobiol Dis, 18(1): 134-42. [Abstract] [Full-text]
27. ABCA2 is a strong genetic risk factor for early-onset Alzheimer's disease.
    Neurobiol Dis, 18(1): 119-25. [Abstract] [Full-text]
28. Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice.
    Neurobiol Dis, 18(1): 89-99. [Abstract] [Full-text]
29. ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42.
    Neurobiol Dis, 18(1): 75-82. [Abstract] [Full-text]
30. Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span.
    Neurobiol Dis, 18(1): 32-9. [Abstract] [Full-text]
31. Structure and function of amyloid in Alzheimer's disease.
    Prog Neurobiol, 74(6): 323-49. [Abstract] [Full-text]
32. Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain.
    Brain Res, 1031(2): 222-8. [Abstract] [Full-text]
33. Memory evaluation with a new cued recall test in patients with mild cognitive impairment and Alzheimer's disease.
    J Neurol, 252(1): 47-55. [Abstract] [Full-text]
34. Posterior cortical atrophy: variant of Alzheimer's disease? A case series with PET findings.
    J Neurol, 252(1): 27-35. [Abstract] [Full-text]
35. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
    Bioorg Med Chem, 13(3): 773-83. [Abstract] [Full-text]
36. White matter lesions are associated with cortical atrophy more than entorhinal and hippocampal atrophy.
    Neurobiol Aging, 26(4): 553-9. [Abstract] [Full-text]
37. Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients.
    Neurobiol Aging, 26(4): 455-64. [Abstract] [Full-text]
38. A new promoter polymorphism in the alpha-1-antichymotrypsin gene is a disease modifier of Alzheimer's disease.
    Neurobiol Aging, 26(4): 449-53. [Abstract] [Full-text]
39. Oxidative stress related markers in the "VITA" and the centenarian projects.
    Neurobiol Aging, 26(4): 429-38. [Abstract] [Full-text]
40. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses.
    Neurobiol Aging, 26(4): 393-407. [Abstract] [Full-text]
41. Does the AD7c-NTP locus encode a protein?
    Biochim Biophys Acta, 1727(1): 1-4. [Abstract] [Full-text]
42. Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease.
    J Biol Chem, 280(3): 1790-6. [Abstract] [Full-text]
43. Stimulation of G-proteins in human control and Alzheimer's disease brain by FAD mutants of APP(714-723): implication of oxidative mechanisms.
    J Neurosci Res, 79(3): 368-74. [Abstract] [Full-text]
44. Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin.
    J Neural Transm, 112(2): 269-82. [Abstract] [Full-text]
45. Learning facts from fiction: effects of healthy aging and early-stage dementia of the Alzheimer type.
    Neuropsychology, 19(1): 115-29. [Abstract] [Full-text]
46. The role of color in the implicit memory performance of healthy older adults and individuals with Alzheimer's disease.
    Neuropsychology, 19(1): 44-53. [Abstract] [Full-text]
47. Effects of graded levels of physical similarity and density on visual selective attention in patients with Alzheimer's disease.
    Neuropsychology, 19(1): 5-17. [Abstract] [Full-text]
48. Alternative splicing in the N-terminus of Alzheimer's presenilin 1.
    Neurogenetics, 5(4): 223-7. [Abstract] [Full-text]
49. Comprehensive association analysis of APOE regulatory region polymorphisms in Alzheimer disease.
    Neurogenetics, 5(4): 201-8. [Abstract] [Full-text]
50. Role of the APP promoter in Alzheimer's disease: cell type-specific expression of the beta-amyloid precursor protein.
    Ann N Y Acad Sci, 1030: 310-6. [Abstract] [Full-text]
51. Protective effects of insulin-like growth factor-I on the somatostatinergic system in the temporal cortex of beta-amyloid-treated rats.
    J Neurochem, 92(3): 607-15. [Abstract] [Full-text]
52. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases.
    Eur J Pharm Biopharm, 59(2): 263-72. [Abstract] [Full-text]
53. Application of graph theory: prediction of glycogen synthase kinase-3 beta inhibitory activity of thiadiazolidinones as potential drugs for the treatment of Alzheimer's disease.
    Eur J Pharm Sci, 24(2): 213-8. [Abstract] [Full-text]
54. Metalloproteinase ADAMTS-1 but not ADAMTS-5 is manifold overexpressed in neurodegenerative disorders as Down syndrome, Alzheimer's and Pick's disease.
    Brain Res Mol Brain Res, 133(1): 1-5. [Abstract] [Full-text]
55. Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease.
    Clin Neurophysiol, 116(2): 364-75. [Abstract] [Full-text]
56. Aluminium in Alzheimer's disease: are we still at a crossroad?
    Cell Mol Life Sci, 62(2): 143-58. [Abstract] [Full-text]
57. Evaluation of cholinergic markers in Alzheimer's disease and in a model of cholinergic deficit.
    Neurosci Lett, 375(1): 37-41. [Abstract] [Full-text]
58. Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran.
    Neurosci Lett, 375(1): 1-6. [Abstract] [Full-text]
59. Menatetrenone and vitamin D2 with calcium supplements prevent nonvertebral fracture in elderly women with Alzheimer's disease.
    Bone, 36(1): 61-8. [Abstract] [Full-text]
60. Presenilin 2 familial Alzheimer's disease mutations result in partial loss of function and dramatic changes in Abeta 42/40 ratios.
    J Neurochem, 92(2): 294-301. [Abstract] [Full-text]
61. Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer's disease and link to cognitive impairment.
    J Neurochem, 92(2): 255-63. [Abstract] [Full-text]
62. Alzheimer's disease beta-secretase BACE1 is not a neuron-specific enzyme.
    J Neurochem, 92(2): 226-34. [Abstract] [Full-text]
63. The effects of very early Alzheimer's disease on the characteristics of writing by a renowned author.
    Brain, 128: 250-60. [Abstract] [Full-text]
64. Proneness to psychological distress and risk of Alzheimer disease in a biracial community.
    Neurology, 64(2): 380-2. [Abstract] [Full-text]
65. Prediction of on-road driving performance in patients with early Alzheimer's disease.
    J Am Geriatr Soc, 53(1): 94-8. [Abstract] [Full-text]
66. Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition.
    J Am Geriatr Soc, 53(1): 83-7. [Abstract] [Full-text]
67. Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo.
    FEBS Lett, 579(3): 753-6. [Abstract] [Full-text]
68. Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria?
    Biochem Biophys Res Commun, 328(1): 1-5. [Abstract] [Full-text]
69. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897.
    Biochem Pharmacol, 69(4): 689-98. [Abstract] [Full-text]
70. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease.
    Proc Natl Acad Sci U S A, 102(4): 1211-6. [Abstract] [Full-text]
71. Ginger extract inhibits beta-amyloid peptide-induced cytokine and chemokine expression in cultured THP-1 monocytes.
    J Altern Complement Med, 10(6): 1009-13. [Abstract] [Full-text]
72. Frontotemporal dementia, semantic dementia, and Alzheimer's disease: the contribution of standard neuropsychological tests to differential diagnosis.
    J Geriatr Psychiatry Neurol, 18(1): 39-44. [Abstract] [Full-text]
73. Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer's disease: a preliminary study.
    J Geriatr Psychiatry Neurol, 18(1): 12-9. [Abstract] [Full-text]
74. Plasma homocysteine levels and cognitive status in long-term stay geriatric patients: a cross-sectional study.
    Arch Gerontol Geriatr, 40(2): 129-38. [Abstract] [Full-text]
75. Methionine oxidation by reactive oxygen species: reaction mechanisms and relevance to Alzheimer's disease.
    Biochim Biophys Acta, 1703(2): 111-9. [Abstract] [Full-text]
76. Paradoxical features of word finding difficulty in primary progressive aphasia.
    Ann Neurol, 57(2): 204-9. [Abstract] [Full-text]
77. Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.
    Clin Chem, 51(2): 336-45. [Abstract] [Full-text]
78. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.
    FASEB J, 19(2): 255-7. [Abstract] [Full-text]

© 2004-2008 Alzheimer's Disease Research Today. All Rights Reserved.